|Dr. Errol B. De Souza||Exec. Chairman||280.58k||N/A||1953|
|Mr. Adrian Hinton||Acting Chief Financial Officer||205.06k||N/A||N/A|
|Prof. Paul Rolan||Consultant Chief Medical Officer of Clinical Neuroscience||N/A||N/A||N/A|
|Ms. Suzanne Irwin B.Com., FCIS||Company Sec.||N/A||N/A||N/A|
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.
Bionomics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.